CTIS2024-513295-18-00招募中1 期
Pilot phase II study of Selinexor in combination with Ifosfamide, Etoposide and Dexamethasone (SIDE) in patients with relapsed or refractory Peripheral T-cell Lymphomas - PTCL S-IDE
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care, Patients must be accessible for treatment and follow up as well as they must be willing and capable to comply with the requirements of the study, Confirmed availability of archival or freshly collected tumor tissue, Life expectancy of at least 3 months, Absence of central nervous system (CNS) involvement at the moment of enrollment, No previous medical history of psychiatric disease, Normal organ function: clearance creatininine = 40 mL/min; ejection fraction > 50%; Levels of serum bilirubin, alkaline phosphatase and transaminases < 2 the upper normal limit, if not disease related, Histologically confirmed diagnosis of angioimmunoblastic T cell lymphoma (AITL), anaplastic large cell lymphoma ALK negative lymphoma (ALK neg), peripheral T cell lymphoma not otherwise specified (PTCL-NOS), or T helper follicular lymphoma (TFH) according to 2016 WHO classification, Age > 18 and < 75, Must have measurable disease defined by at least 1 fluorodeoxyglucose (FDG)-avid lesion for FDG-avid subtype and 1 bi-dimensionally measurable (> 1.5 cm in longest diameter) disease by computed tomography (CT) or magnetic resonance imaging (MRI), as defined by the Lugano classification, Eastern Cooperative Oncology Group (ECOG) performance status of ECOG =2, Female patients of reproductive potential should avoid becoming pregnant by using a highly effective method of contraception or abstaining from sexual activity while being treated with selinexor and for at least 90 days following the last dose of selinexor. Female subject is either: • post-menopausal for at least one year before the screening visit, or • surgically sterilized, or • willing to use an acceptable method of birth control (ie, a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study., Male patients of reproductive potential should use an effective method of contraception and are recommended to use a barrier method or abstain from sexual activity while being treated with selinexor and for at least 90 days following the last dose of selinexor. Male subject, even if surgically sterilized (ie, status postvasectomy), agrees to use an acceptable method for contraception during the entire study treatment period through 90 days following the last dose of selinexor, Relapsed or refractory disease after at least one previous line of anti-lymphoma treatment containing anthracycline (including or not high dose chemotherapy and stem cell transplantation as part of the program), Must have the following laboratory values: a. Absolute neutrophil count (ANC) = 1.5 x 109/L or = 1.0 x 109/L in case of documented bone marrow involvement (> 50% or tumor cells), without growth factor support for 7 days (14 days if pegfilgrastim). b. untransfused Hemoglobin (Hb) = 8 g/dL. c. Platelets (PLT) = 75 x 109/L or = 50 x 109/L in case of documented bone marrow involvement (> 50% or tumor cells), without transfusion for 7 days. d. Aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine aminotransferase / serum glutamic pyruvic transaminase (ALT/SGPT) = 2.5 x ULN. e. Serum total bilirubin = 1.5 ULN except in cases of Gilbert’s syndrome, then = 3.0 ULN. f. Estimated serum cre
排除标准
- •Any significant medical condition, or psychiatric illness that would prevent the subject from participating in the study, Contraindication to any of the required concomitant drugs or supportive treatments, Patient has received other investigational drugs within 30 days before enrollment, Other severe acute or chronic medical or psychiatric condition, including uncontrolled diabetes, malabsorption, resection of the pancreas or upper small bowel, requirement for pancreatic enzymes, any condition that would modify small bowel absorption of oral medications, or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for enrollment in this study, Diagnosed or treated for another malignancy within 3 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy, Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study, Active, unstable cardiovascular function, as indicated by the presence of: o Symptomatic ischemia, or o Uncontrolled clinically significant conduction abnormalities (eg, patients with ventricular tachycardia on anti-arrhythmics are excluded; patients with first degree atrioventricular block or asymptomatic left anterior fascicular block/right bundle branch block will not be excluded), or o Congestive heart failure of New York Heart Association Class =3 or known left ventricular ejection fraction <40%, or o Myocardial infarction within 6 months prior to C1D1, Female subject who is pregnant or breast-feeding. Confirmation that the subject is not pregnant must be established by a negative serum ß-human chorionic gonadotropin (ß-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women., Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within 1 week prior to Cycle 1 Day 1 (C1D1). Patients on prophylactic antibiotics or with a controlled infection within 1 week prior to treatment initiation are acceptable, Prior radiation therapy within 30 days prior to starting SIDE, Prior to study entry, any ECG abnormality at Screening has to be documented by the investigator as not medically relevant. Prior to study entry, any ECHO or MUGA scan abnormality at Screening has to be documented by the investigator as not medically relevant, Subjects with active hepatitis B virus (HBV) or active hepatitis C (HCV), Known seropositivity for or active viral infection with human immunodeficiency virus (HIV), Any active gastrointestinal dysfunction interfering with the patient’s ability to swallow tablets, or any active gastrointestinal dysfunction that could interfere with absorption of study treatment
研究者
相似试验
尚未招募
Unknown
Phase 1/2 study of Selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with secondary central nervous system involving relapsed or refractory B-cell non-Hodgkin lymphoma: a single arm, open label, multicenter studyKCT0008884Samsung Medical Center35
进行中（未招募）
1 期
A study of selinexor in combination with imatinib in patients with metastatic and/or unresectable gastrointestinal tumors (GISTs)EUCTR2017-004761-28-ESGrupo Español de Investigación en Sarcomas41
招募中
2 期
A Phase II study of Selinexor (KPT-330) combined with bortezomib and dexamethasone (SVd) for induction and consolidation for patients with progressive or refractory Multiple Myeloma.10018865Multiple MyelomaNL-OMON44193Erasmus MC, Universitair Medisch Centrum Rotterdam49
进行中（未招募）
1 期
A Phase II study of Selinexor (KPT-330) combined with bortezomib and dexamethasone (SVd) for induction and consolidation for patients with progressive or refractory Multiple Myeloma.A Phase II study of Selinexor (KPT-330) combined with bortezomib and dexamethasone (SVd) for induction and consolidation for patients with progressive or refractory Multiple Myeloma.EUCTR2014-002444-40-NLErasmus MC37
尚未招募
不适用
A Phase II study of Selinexor (KPT-330) combined with bortezomib and dexamethasone (SVd) for induction andconsolidation for patients with progressive or refractory Multiple Myeloma.Multiple MyelomaMultipel MyeloomProgressive or RefractoryProgressief of refractairsafety and tolerability of selinexorNL-OMON25937Erasmus University Medical Center49